|[January 14, 2013]
Critical Diagnostics Becomes An Affiliated Member of The Healthcare Accreditation Colloquium
SAN DIEGO --(Business Wire)--
Critical Diagnostics, makers of the Presage® ST2 Assay, a novel
biomarker for use in heart failure patient care, announced today that it
has joined Healthcare Accreditation Colloquium, an organization of heart
failure experts seeking to build the healthcare system of the future.
"The Colloquium's primary objective, to develop a cohesive and
integrated approach for heart failure management, aligns perfectly with
Critical Diagnostics' efforts to integrate ST2 in the continuum of care
to improve patient outcomes," notes James Snider, President of Critical
"We welcome Critical Diagnostics as a member," said Colloquium CEO, Tony
Joseph, MD. "Application of the Presage ST2 Assay across the
Colloquium's entire continuum of care model is likely to change how we
all think about heart failure and improve the lives of our patients."
On January 30, 2013, the Colloquium will host a webinar, "Beyond The
Natriuretic Peptides for Management of Heart Failure: An Expert Panel
Review of a Novel Biomarker, ST2," featuring James Januzzi, M.D., of
Massachusetts General Hospital, along with James Snider, Ph.D, President
of Critical Diagnostics, and facilitated by Tony Joseph, M.D., of the
"Heart failure is a chronic progressive illnss that challenges the best
clinician," begins the description of the webinar. "Disease progression
is often masked by absence of observable clinical changes, while the
neuro-hormonal abnormalities continue unabated. The natriuretic peptides
have established a role in the diagnosis of heart failure, however,
their ability to bridge the gap in prognosis has fallen short in the
management of these patients. Novel cardiac biomarkers, like ST2,
provide additional information that enables the delivery of focused care
to those patients needing it most in a timely fashion, which has the
potential to significantly improve outcomes."
Colloquium members have access to the webinar by invitation. Non-members
can take part by contacting the Colloquium at colloquiumhealth.com/contact.
Soluble ST2 has now been published in more than 100 peer-reviewed
articles and scientific posters studying more than 35,000 patients.
These clinical studies have demonstrated that high levels of soluble ST2
are predictive of adverse patient outcomes and death in a broad spectrum
of cardiovascular disease. They have further shown that the prognostic
information from soluble ST2 is independent of, and provides added
information to, that of cardiac biomarkers commonly used today. The
Presage ST2 Assay has been CE Marked and cleared by the US FDA.
About Critical Diagnostics
Critical Diagnostics (www.criticaldiagnostics.com)
develops novel biomarkers to help physicians optimize patient care in
cardiovascular diseases, while containing healthcare costs.
About Healthcare Accreditation Colloquium
The Healthcare Accreditation Colloquium is a hospital membership
organization - a Colloquium - of Heart Failure Experts working together.
The Colloquium's improvement methodology covers the entire continuum of
care and leads to becoming a Colloquium Accredited Heart Failure Center
or Institute - an important distinction for those seeking pre-eminence
in their market.
[ Back To Technology News's Homepage ]